seeing increased investigation in clinical trials for treatment of hematological malignancies. These compounds also repress oncogene expression driven by the human Epstein-Barr virus (EBV) in cell culture. We therefore tested the efficacy of the prototypical BET inhibitor JQ1 against a mouse xenograft model of post-transplantation lymphoproliferative disorder. JQ1 potently inhibits growth of lymphoblastoid cell lines (LCLs) in culture at low nM concentrations. Growth of other cell lines with similar EBV type III latency transcription programs is comparably inhibited. JQ1 also slows tumor development of an LCL xenograft in immunocompromised mice, but oncogene repression is not observed in endpoint biopsies. We find reduction of EBV-associated lymphoproliferative disease in an animal model encouraging of further studies.
Emerging preclinical evidence highlights the potential for inhibitors of BET proteins in treating hematological malignancies. These compounds occlude the ligandbinding pockets of bromodomains and prevent recruitment toward acetylated lysine substrates [1, 2] . This activity is leveraged in therapeutic approaches to repress oncogene expression by interfering with transcriptional enhancers. For example, tumor growth is inhibited in mouse models of lymphoma dependent on overexpression of the MYC oncogene driven by the BET protein BRD4 [3, 4, 5] . Whether BET inhibitors can similarly repress induced oncogenes to yield efficacy against EBV-associated lymphoproliferative disease in vivo remained to be tested.
Efficacy trials of BET inhibitors with EBV-associated malignancies in animal models have so far been limited. EBV immortalizes B cells and is associated with a proportion of malignancies and lymphoproliferative diseases. To facilitate cell growth, EBV increases expression of MYC and other oncogenes by producing transcription factors that bind super-enhancers containing BRD4 [6] . JQ1 displays antiproliferative effects against the EBV-infected Raji cell line in a mouse xenograft model of Burkitt lymphoma [3] . Raji viral genomes, however, contain a deletion that results in an atypical transcription profile [7] not commonly found in tumors. LCLs, B cells immortalized by EBV in vitro, display a viral transcription program similar to that observed in lymphoproliferative disease among immunosuppressed individuals [8] and serve as commonly tested mouse xenograft models for such lesions [9] . The GM12878 LCL in particular has been heavily examined as part of ENCODE consortium [10] . In this study, we test JQ1 for efficacy in this mouse model of post-transplantation lymphoproliferative disorder. JQ1 inhibits growth of LCLs at low nM concentration in cell culture. Treatment with JQ1 reduces GM12878 cell growth at a concentration of 500 nM in cell culture [6] .
We determined a complete dose response against the active (+)-JQ1 isomer to define a more quantitative measure of potency. Cells at a density of 0.3×10 6 /mL were treated with JQ1 (Selleck Chemicals) in DMSO and counted with a hemacytometer after 3 days. Changes in cell density were normalized against the DMSO vehicle control. We measured an IC 50 of 134 ± 26 nM ( Figure 1(A) ). Similar results were obtained with the 721 LCL (data not shown). Low nM IC 50 concentrations suggest potential potency for use in vivo.
We further queried the specificity of JQ1 against lymphoma cell lines harboring EBV to determine the generality of responsiveness. Variant strains express different stereotyped transcription programs referred to as latency types. Type III latency expresses transcription factors that assemble EBV super-enhancers, which are sensitive to JQ1 treatment, to possibly promote oncogene expression. Type I latency does not express the same factors. We examined two sets of isogenic Burkitt lymphoma lines that exhibit different viral transcription programs [7] : (Figure 1(B) ). Tumor size decreases ~2-fold after 3-4 weeks. We obtained contrasting results with a xenograft model of Burkitt lymphoma.
When MutuI cells were implanted into mice with the same protocol, we observed no statistically significant difference in tumor size with JQ1 treatment (Figure 1(B) ). The higher IC 50 value in cell culture may explain the lack of efficacy against MutuI cells in xenografts. For the GM12878 LCL treated with JQ1, the low nM IC 50 value in vitro translates to reduction of EBV-associated lymphoproliferation in vivo.
Transcriptional profiling of tumors surprisingly detected minimal perturbation after JQ1 treatment. We searched for potential antitumor mechanisms in the GM12878 xenograft with RNA deep sequencing (RNA-seq). Specimens were excised in ~30 mm 3 slices from mice after 1 month of JQ1 treatment and ~5 hours after the final dose.
Biopsies were stored in RNAlater (Qiagen) at -80 °C and disrupted with a pellet pestle (Kimble Chase) in RLT Buffer (Qiagen). RNA was purified, processed, and sequenced according to our RNA-seq protocol [7] . Data analysis was performed with the usegalaxy.org instance of Galaxy [11] : reads were aligned to the UCSC hg19 human genome reference sequence with HiSAT version 2.0.3 [12] , gene-level expression abundance measured using the UCSC hg19 RefSeq annotation with featureCounts version 1.4.6-p5 [13] , and differentially expressed genes identified with DESeq2 version 1.14.1 [14] . Every data set yielded ~10-40 million mapped reads. Comparing three samples each of JQ1-and vehicle-treated biopsies, hierarchal clustering reveals little distinction between transcriptome profiles based on JQ1 treatment (Figure 1(C) ). (Figure 1(D) ). MYC expression levels are not reduced. We also examined BCL2 and RUNX3, genes also controlled by EBV superenhancers [6] . Again, we found no repression. Even expanding our search to genes important for LCL growth proximal to EBV super-enhancers [6] did not detect any significant transcriptional changes. JQ1 pharmacokinetics may be responsible for the lack of transcriptional perturbation, but MYC repression occurs in physiologically similar Raji xenografts of NOD/SCID mice 4 and 8 hours after dosing with 25 mg/kg JQ1 [3] . We favor the possibility that the GM12878 LCL escapes oncogene repression through rapidly acquired resistance to JQ1 treatment. Our observation that GM12878 xenografts do not display sustained oncogene repression should emphasize this weakness as a point of optimization in BET inhibitor therapeutic strategies.
Concordant
Although our experiments demonstrate only partial reduction of tumor growth in a mouse xenograft model, we still advocate further research into the use of BET inhibitors for treating EBV-associated post-transplantation lymphoproliferative disorder. BET inhibitors are already seeing increasing use in clinical trials, generating a wealth of data in the context of B cell malignancies. Moreover, not only do BET inhibitors target oncogene expression driven by EBV proteins [6] , but our own work shows that the same compounds also block EBV lytic gene expression [15] , a contributing factor [9] to lymphoproliferative disease. This potential therapeutic deserves investigation in further preclinical animal models.
